HealthDay.com
Caution: Increasing Trend of Foraging for Mushrooms
Wrong choices can lead to liver failure, death, researchers warn
Second Severe Allergic Reaction Within Hours Isn’t Uncommon
Researchers find about one in seven children have repeat episode
Alcohol Use Appears to Impair Driving More Than Cannabis Use
And combination of the two increases risks but effect isn't doubled
Fat Grafting Widely Used During Facelift Surgery
Survey results from random sample of members of the American Society of Plastic Surgeons
Facility Costs of Hospital Birth Vary by Nearly $10K Across U.S.
Evaluation of hospital practices may offer opportunities for cost reduction
Uncontrolled Diabetes Linked to Increased Risk of Dementia
Older patients with more disease complications have greater cognitive decline
ASCO Updates Guidelines for Colony-Stimulating Factor Use
Special article updates 2006 guidelines, including addition of tbo-filgrastim and filgrastim-sndz
Progress in Reporting Conflict of Interest Among IRB Members
Percentage of members who felt another member didn't disclose financial relationships down '05 to '14
Arts Observation Curriculum May Be Beneficial for Medical Students
Learning to observe objectively and communicate observations important in clinical practice
![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
